The FDA's Vaccine and Related Biological Products Advisory Committee met last week. The primary and unprecedented purpose of their meeting was to instill confidence in their approval process, which has suffered from grandstanding by political leaders of all shapes and sizes. The secondary but still important mission was to showcase their standards for safety and efficacy including post-approval monitoring.
Please join me and Josh Trantum, Ph.D. for a discussion on the meeting, its messages, timing and what we think the next few months will look like. We will also talk about scenarios for approval and conditions of an EUA.
Thursday, October 29 @ 12:30PM ET (Add to Outlook Calendar)
CLICK HERE for event details (includes video and materials link)
About Josh Trantum: Josh has extensive experience sourcing, licensing and developing pre-clinical biopharmaceutical assets in a broad range of therapeutic categories and disease areas. He also holds an adjunct appointment as an assistant professor in Biomedical Engineering at the Vanderbilt University School of Engineering. You will want to tune in because Josh is great at translating scientific discovery into investment opportunity, something he does each day at his life sciences fund, Curex Capital.